Core Viewpoint - The collaboration between药捷安康 and Neurocrine Biosciences aims to develop NLRP3 inhibitors for treating various diseases, with a total potential value of $881.5 million [1] Group 1: Agreement Details -药捷安康 has entered into a patent transfer and research collaboration agreement with Neurocrine Biosciences, granting Neurocrine exclusive rights for development, manufacturing, and commercialization outside Greater China, while retaining rights in Greater China [1] - The agreement includes an upfront payment to药捷安康, with potential milestone payments based on development and commercialization progress [1] - The total potential value of the agreement is $881.5 million, which also encompasses research collaboration to further develop NLRP3-related technologies [1] Group 2: Scientific Background - NLRP3 inflammasome is a crucial inflammatory complex within myeloid cells, with elevated activation levels closely associated with insulin resistance [1] - Chronic low-grade inflammation, triggered in states of obesity or metabolic disorders, can disrupt insulin signaling and exacerbate insulin resistance [1] - Inhibiting NLRP3 can reduce inflammatory responses and lower reactive oxygen species (ROS) production, thereby improving the cellular metabolic environment [1]